Clinical Scorecard: Retina Biomarkers for Treatment Selection in DME

At a Glance

Key Highlights

• DME is a leading cause of vision loss, with prevalence expected to rise significantly.
• Anti-VEGF therapy is the gold standard for center-involving DME, with newer agents allowing extended intervals.
• Imaging biomarkers from OCT and OCTA are crucial for treatment stratification and monitoring.
• Resistance to anti-VEGF occurs in about 40% of patients, necessitating alternative therapies.
• Corticosteroids serve as second-line agents, particularly for patients with specific retinal characteristics.

Guideline-Based Recommendations

Diagnosis

• Utilize multimodal imaging including OCT, FA, and OCTA for comprehensive assessment.

Management

• Initiate anti-VEGF therapy as first-line treatment; consider corticosteroids for resistant cases.

Monitoring & Follow-up

• Regular OCT imaging to assess central subfield thickness and retinal structure.

Risks

• Corticosteroids may lead to cataract formation and increased intraocular pressure.

Patient & Prescribing Data

Patients with DME, particularly those showing resistance to anti-VEGF therapy.

Imaging biomarkers can guide treatment decisions and predict responses to therapy.

Clinical Best Practices

• Incorporate OCT findings in treatment planning and monitoring.
• Evaluate the presence of specific OCT biomarkers to tailor therapy.
• Consider transitioning to corticosteroids in cases of ELM or EZ discontinuity.

Related Resources & Content

• Diabetic Macular Edema Epidemiology
• Anti-VEGF Therapy Guidelines
• OCT Imaging in DME